Please login to the form below

Not currently logged in

New hires at Nanoform, Leo Pharma and Calliditas

The latest movers in pharma and biotech

Nanoform names new chief technology officer

Dr Niklas Sandler is named as Nanoform’s new chief technology officer (CTO), a role that will see Sandler combine pharmaceutical R&D with his commercial expertise to develop technological resources.

Niklas Sandler

Dr Niklas Sandler, incoming chief technology officer, Nanoform

Sandler succeeds acting CTO Dr Jouko Yliruusi, who together with Nanoform chief Dr Edward Hæggström, has led the development of the company’s particle engineering technology during the last 10 years.

Hæggström said: “I am delighted to welcome Niklas Sandler to Nanoform. His exceptional experience in pharmaceutical technology and product development will be a huge asset to the company and allow us to set ambitious goals to enhance our commercial offering.”

Sandler comes to Nanoform with extensive experience in both industry and academia, particularly in pharmaceutical product development and material science.

His most recent role was Vice Rector, responsible for Research Affairs and Professor of Pharmaceutical Technology at Åbo Akademi University, Finland.

Sandler said: “I am excited to be joining Nanoform’s dynamic environment and a team that is passionate about transforming the pharmaceutical industry. My career has focused on enhancing the commercial application of research, and Nanoform’s use of cutting-edge nanonization technology exemplifies how innovations are transforming the sector.”

Leo Pharma boosts Translational Medicine team

Adam Raff will soon join dermatology-focused Leo Pharma, heading up the company’s new Translational Medicine Unit as director and medical advisor.

Adam Raff

Adam Raff, Director, Translational Medicine Unit, Leo Pharma

He is due to start towards the end of this month, and will support Leo’s ambitions to advance science within dermatology through translational medicine.

Raff currently works as a dermatologist at the Department of Dermatology at Massachusetts General Hospital, Boston, MA as well as a Dermatology Instructor at Harvard Medical School, Boston, MA.

Calliditas Therapeutics appoints VP Regulatory Affairs

Calliditas Therapeutics has appointed Dr. Frank Bringstrup as Vice President Regulatory Affairs effective February 1, 2019.

As a member of the management team, Bringstrup will have a leading role in the regulatory discussions and approval process of the company’s phase 3 study NEFIGARD in patients with IgA nephropathy (IgAN) – also known as Berger’s disease.

“I am delighted to welcome Frank to the team at this exciting stage in the company’s development. The combination of his strong experience in regulatory affairs, not only with the FDA but on a broad international basis with a proven track record and experience from orphan drug development and bringing products to market will play a key role as we progress development of Nefecon through phase 3 clinical trials”, said Renée Aguiar-Lucander, CEO of Calliditas Therapeutics.

Bringstrup brings over 17 years’ experience in the pharmaceutical industry in regulatory affairs and health authority interactions. He has previously worked in various positions at Novo Nordisk, most recently as its Senior Global Regulatory Lead.

During his time at Novo Nordisk, he led the strategic regulatory input for the orphan drug NovoEight from phase 1 through phase 3.

He said: “I am excited to take on this role at Calliditas. With the phase 3 trial of Nefecon well underway, this is a pivotal time for the company. Currently, there are no approved treatments for IgA Nephropathy, and Nefecon has the potential to be a disease-modifying treatment for patients suffering from this chronic autoimmune disease.

“I am delighted to be working with this dynamic team to progress the development of Nefecon through to market.”

15th January 2019

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....